Format

Send to

Choose Destination
Lancet. 1991 Sep 14;338(8768):661-2.

Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis.

Author information

1
Department of Immunogenetics, Guy's Hospital, London, UK.

Abstract

75 systemic sclerosis patients were independently tested for pulmonary fibrosis, autoantibodies, and MHC class II genes. 24 of 42 (57%) patients with pulmonary fibrosis had either HLA DR3/DRw52a or anti-Scl-70 vs 2 of 33 (6%) patients without pulmonary fibrosis. The presence of DR3/DRw52a or anti-Scl-70 gives a relative risk of 16.7 for the development of pulmonary fibrosis in a patient with scleroderma--a risk substantial enough to require careful monitoring of these patients and treatment at an early stage of disease.

PMID:
1679476
DOI:
10.1016/0140-6736(91)91235-m
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center